Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Using Tranexamic Acid and Vitamin K to Treat Upper Gastrointestinal Bleeding in Cirrhotic Patients

Official title: Efficacy of Tranexamic Acid and Vitamin k Injection in Control of Upper Gastrointestinal Bleeding in Egyptian Cirrhotic Patients: A Randomized Controlled Study

Run by Tanta University · NCT06881628 · Data updated 2026-11-12

This study is testing whether giving Tranexamic acid and vitamin K can help control bleeding in the stomach for people with liver cirrhosis.

More Cirrhosis trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment194 (estimated)
SponsorTanta University
Academic / other
Locations1 site (Tanta, Gharbyea)
StatusRecruiting
StartedDecember 2, 2024
Main results expectedDecember 15, 2025
Study endsDecember 30, 2025
Registry record updatedMarch 18, 2025
Trial IDNCT06881628 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older with liver cirrhosis and upper gastrointestinal bleeding.

Probably not a fit

Patients under 18 years old, those with allergies to the study medications, or those with certain medical conditions such as end-stage renal disease will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the effectiveness of Tranexamic acid and vitamin K injections in controlling upper gastrointestinal bleeding (UGIB) among Egyptian patients with liver cirrhosis. Participants experiencing variceal bleeding will be randomly assigned to receive either the active treatment or a placebo, with outcomes measured in terms of bleeding and mortality rates at 5 days and 6 weeks following endoscopic intervention. The study will also ensure that all patients receive standard initial management for their condition. The trial is designed to provide insights into the potential benefits of these interventions in a specific patient population.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce bleeding and mortality rates in cirrhotic patients experiencing UGIB.

How similar studies have gone: While the specific combination of Tranexamic acid and vitamin K for this indication may be novel, similar studies have shown promise in using Tranexamic acid for bleeding control in various contexts.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years
* Liver cirrhosis
* Upper gastrointestinal bleeding

Exclusion Criteria:

* Patients aged \< 18 years
* Allergy to tranexamic acid
* Allergy to vitamin K injection
* DIC.
* Thromboembolic event.
* Pregnancy or lactation.
* End-stage renal disease.
* Unwilling to participate in our study.

Where it's running

  • Tanta University Hospitals
    Tanta, Gharbyea, Egypt
    Recruiting

Study contacts

  • Principal investigator: Rania M Elkafoury, MD — Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
  • Study coordinator: Rania M Elkafoury, MD
  • Email: rania.elkafoury@med.tanta.edu.eg
  • Phone: +201004672358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.